30 completed, 4 withdrawn, 3 terminated, 3 unknown. 20 Phase 2, 13 Phase 1, 5 Phase 4, 4 Phase 3, 3 Not applicable.
Follow Sinemet: new trials by email Literature Review of Sinemet trials Research Report on Sinemet
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg - Parkinsonian Signs in Older Persons | Phase 1 / Phase 2 | Completed | University of Michigan | 5 | 2024-10-29 | 2026-04-14 |
| Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg, Placebo 1 - Parkinsonian Signs in Older Persons | Phase 1 / Phase 2 | Completed | University of Michigan | 13 | 2024-03-15 | 2025-06-17 |
| Novel Non-opioid Post-surgical Pain Treatment in Females Carbidopa-Levodopa (100mg/25mg):, Naproxen - Acute Pain, Bunionectomy | Phase 2 | Withdrawn | Northwestern University | 2021-11-01 | 2024-03-18 | |
| Levodopa and Exercise for Older Adults With Depression and Psychomotor Slowing Carbidopa/levodopa, Placebo, Exercise training - Depressive Disorder | Phase 4 | Terminated | New York State Psychiatric Institute | 1 | 2021-10-07 | 2023-02-02 |
| 1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study) Carbidopa/levodopa, Placebo - Depression, Cognitive Impairment | Phase 4 | Terminated | New York State Psychiatric Institute | 5 | 2021-02-10 | 2023-05-22 |
| Improving Quality of Life in Early Parkinson's Disease Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet, Citalopram - Parkinson Disease, Depression | Not applicable | Unknown | Western University, Canada | 30 | 2021-01-01 | 2020-10-19 |
| Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet, Naproxen 500 Mg, Opioids - Opioid Use, Opioid Dependence | Phase 2 | Active not recruiting | Northwestern University | 60 | 2021-01-01 | 2024-11-27 |
| Effects of 5HTP and LDOPA on CNS Excitability After SCI 5HTP, L-DOPA, Placebo oral tablet - Spinal Cord Injuries | Phase 2 / Phase 3 | Suspended | Jessica M D'Amico | 30 | 2019-06-19 | 2022-10-17 |
| Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis carbidopa-levodopa, Placebo Oral Tablet - Amyotrophic Lateral Sclerosis, Motor Neuron Disease | Phase 1 | Completed | Washington University School of Medicine | 15 | 2019-05-13 | 2022-07-11 |
| Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) CVT-301, Sinemet - Parkinson's Disease | Phase 1 | Completed | Acorda Therapeutics | 23 | 2019-03-05 | 2019-08-02 |
| PF 06412562 in Subjects With Advanced Stage Parkinson's Disease PF-06412562, Standard of Care Placebo - Parkinson Disease | Phase 1 | Completed | Milton S. Hershey Medical Center | 8 | 2018-09-24 | 2019-07-31 |
| A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa. Opicapone, Carbidopa Levodopa - Parkinson Disease | Phase 1 | Completed | Neurocrine Biosciences | 16 | 2018-02-08 | 2019-03-22 |
| Extension, Carbidopa-levodopa in Neovascular Age-related Macular Degeneration (AMD) carbidopa-levodopa 25-100 mg - Macula; Degeneration, Retina | Phase 2 | Completed | Snyder, Robert W., M.D., Ph.D., P.C. | 35 | 2017-08-01 | 2025-09-12 |
| Carbidopa-levodopa in Neovascular AMD carbidopa-levodopa 25-100 mg tablets - Age-related Macular Degeneration | Phase 2 | Completed | Snyder, Robert W., M.D., Ph.D., P.C. | 20 | 2017-05-02 | 2025-09-12 |
| Dose Ranging Study of Carbidopa-levodopa Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet - Age-related Macular Degeneration | Phase 2 | Completed | Snyder, Robert W., M.D., Ph.D., P.C. | 35 | 2017-05-02 | 2025-09-12 |
| Pharmacokinetic of Levodopa Study in Healthy Males Levodopa, carbidopa, ODM-104 - Parkinson Disease | Phase 1 | Completed | Orion Corporation, Orion Pharma | 20 | 2017-04-19 | 2017-09-26 |
| Dose-finding Pharmacokinetic Study in Healthy Males Levodopa, Carbidopa, ODM-104 - Healthy Volunteers | Phase 1 | Completed | Orion Corporation, Orion Pharma | 56 | 2017-02-21 | 2021-05-27 |
| A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease Sinemet, IPX203 - Advanced Parkinson's Disease | Phase 2 | Completed | Impax Laboratories, LLC | 28 | 2016-11-14 | 2022-06-06 |
| A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease CD-LD IR, IPX203 180 mg, IPX203 270 mg - Parkinson's Disease | Phase 2 | Completed | Impax Laboratories, LLC | 26 | 2015-11-01 | 2019-11-06 |
| Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa Levodopa+carbidopa, Placebo - Depression | Phase 4 | Completed | Emory University | 57 | 2015-10-09 | 2022-09-19 |
Showing 20 of 42. Sign in to see all of them.
Parkinson Disease (15) · Angelman Syndrome (3) · Cocaine-Related Disorders (3) · Depression (3) · Pain (3) · Stroke (3) · Acute Pain (2) · Macular Degeneration (2) · Opioid-Related Disorders (2) · Substance-Related Disorders (2) · Albinism (1) · Albinism, Oculocutaneous (1) · Alcoholism (1) · Amyotrophic Lateral Sclerosis (1) · Anhedonia (1)
Orion Corporation, Orion Pharma (5) · Northwestern University (4) · Snyder, Robert W., M.D., Ph.D., P.C. (3) · Bial - Portela C S.A. (2) · Emory University (2) · Impax Laboratories, LLC (2) · New York State Psychiatric Institute (2) · The University of Texas Health Science Center, Houston (2) · University of Michigan (2) · Aarhus University Hospital (1) · Acorda Therapeutics (1) · Bennett Lavenstein (1) · Boston Children's Hospital (1) · Centre for Addiction and Mental Health (1) · Jessica M D'Amico (1)
United States (29) · Finland (5) · Canada (2) · Germany (2) · Romania (2) · Ukraine (2) · Austria (1) · Belgium (1) · Denmark (1) · France (1) · Greece (1) · Italy (1) · Portugal (1) · Spain (1) · Sweden (1)
Robert W Snyder, MD, PhD (3) · Apkar V Apkarian, PhD (2) · Bret R Rutherford, MD (2) · Chatkaew Pongmala, PhD (2) · Mika Scheinin, MD (2) · Timothy C Fagan, MD (2) · Wen-Hann Tan, BMBS (2) · Angela L Stotts, PhD (1) · Anne Slavotinek, MD (1) · Apkar Apkarian, PhD (1) · Bennett Lavenstein, MD (1) · Carlos A. Bacino, MD (1) · Cary Fu, MD (1) · Cathrin M Buetefisch, MD (1)
PMID 11391738, PMID 12498954, PMID 16874752, PMID 17138744, PMID 19127579, PMID 19146929, PMID 19190638, PMID 19846332, PMID 19877202, PMID 20582993, PMID 25758422, PMID 32482490, PMID 32986682, PMID 34032202, PMID 34374961, PMID 35927580
R01DE022746 (2), U01AG061393 (2), 2008 (1), 2009 (1), K24MH122514 (1), P50DA009262 (1), R01DA023608 (1), R01DA034131 (1), R01MH109637 (1), R01MH123660 (1), R01NS060830 (1)